Aprea Therapeutics Inc

NAS:APREHealthcarenasdaq_composite

——At close · Market cap — · Next earnings Thu 5 Nov

APRE · Income statement · TradingHolo

USD millions	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	TTM	YoY
Revenue	0.0	0.0	0.0	0.6	1.5	0.0	0.0	—
Cost of revenue	0.2	0.3	16.4	0.0	9.4	0.0	0.0	—
Gross profit	(0.2)	(0.3)	(16.4)	0.6	(7.9)	0.0	(0.0)	—
Research & development	37.9	23.9	92.4	7.6	9.4	7.0	—	—
Selling, general & administrative	14.9	13.6	21.0	8.4	6.5	6.5	—	—
Selling & marketing	0.0	0.0	0.0	(0.0)	0.0	0.0	—	—
Operating expenses	52.8	37.2	97.0	16.0	6.5	13.2	13.2	−0.1%
Operating income	(52.8)	(37.4)	(113.4)	(15.5)	(14.3)	(13.2)	(13.2)	+0.1%
Interest expense	0.2	0.0	0.4	0.0	0.0	0.0	0.0	—
Interest income	0.2	0.0	0.4	1.2	1.3	0.7	—	—
Other income / expense	(0.7)	0.3	0.7	1.2	1.4	0.6	—	—
Pre-tax income	(53.5)	(37.1)	(112.7)	(14.3)	(13.0)	(12.6)	(12.3)	+2.3%
Income tax	0.0	0.0	0.0	0.0	0.0	0.0	0.0	—
Net income	(53.9)	(36.5)	(112.7)	(14.3)	(13.0)	(12.6)	(12.3)	+2.3%
Discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	—	—
Other net income adjustments	(0.4)	0.6	0.0	0.0	0.0	0.0	—	—
EPS, basic (per share)	(50.61)	(34.88)	(1,359.79)	(3.95)	(2.35)	(1.93)	(1.29)	+33.2%
EPS, diluted (per share)	(50.61)	(34.88)	(1,359.79)	(3.95)	(2.35)	(1.93)	(1.29)	+33.2%
EBITDA	(53.2)	(36.9)	(37.4)	(14.3)	(12.9)	(12.6)	(13.1)	−3.8%
Depreciation & amortization	0.2	0.3	0.0	0.0	0.0	0.0	0.0	+1.5%
Weighted average shares (shares)	1,056,682	1,064,327	82,852	3,617,607	5,509,921	6,538,722	—	—
Weighted average diluted shares (shares)	1,056,682	1,064,327	82,852	3,617,607	5,509,921	6,538,722	—	—
Gross margin	—	—	—	98.8%	−523.2%	—	−324.9%	—
Operating margin	—	—	—	−2,652.8%	−953.0%	—	−255,025.5%	—
Net margin	—	—	—	−2,449.6%	−862.4%	—	−237,362.8%	—

USD millionsUpdated Wed 12 Aug ·

ⓘ

Amounts are shown in the stated units; per-share amounts and shares are unscaled. Negative amounts are in brackets.

TTM ends 2026-06-30 and uses four consecutive reported quarters.